Anxiety, depression, and quality of life in hepatocellular carcinoma treated with drug-eluting microspheres plus lenvatinib: A prospective study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
BACKGROUND Patients with hepatocellular carcinoma (HCC) often experience considerable psychological distress that affects their quality of life (QoL). AIM To investigate the effects of drug-eluting microsphere - transcatheter arterial chemoembolization (DEM-TACE) combined with lenvatinib on anxiety, depression, and QoL. METHODS This prospective study enrolled 126 patients with primary HCC treated with DEM-TACE combined with lenvatinib from October 2022 to October 2025. Anxiety and depression assessment with the Hospital Anxiety and Depression Scale (HADS) and QoL evaluation with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and HCC-specific module were conducted at baseline and at 3-, 6-, and 12-month. Clinical outcomes, including overall survival, progression-free survival, and adverse events (AEs), were recorded. RESULTS Overall, 58.7% and 61.1% of patients exhibited anxiety and depression at baseline, respectively. After treatment, both psychological status and QoL significantly improved. At 12 months, the prevalence rates of anxiety and depression decreased to 31.0% and 28.6%, respectively (both P < 0.001). The EORTC QLQ-C30 global health status score increased from 52.3 ± 15.7 to 71.2 ± 14.3 (P < 0.001). Physical, role, and emotional functioning scores also significantly improved (all P < 0.001). Treatment-related AEs were generally manageable. Multivariate analysis showed that baseline HADS score, Barcelona Clinic Liver Cancer stage, and tumor response were independent predictors of QoL outcomes (P < 0.05). CONCLUSION DEM-TACE combined with lenvatinib shows an acceptable safety profile and favorable efficacy in improving anxiety, depression, and QoL in patients with HCC. Early psychological assessment and intervention may optimize outcomes.
Fields of Study & Subjects
Hepatocellular Carcinoma Treatment and Prognosis
Cancer survivorship and care
Health and Well-being Studies
Publication details
- Journal / source
- World Journal of Psychiatry
- Volume
- 16
- Issue
- 4
- Publication date
- 27 March 2026
- Language
- EN